Multicenter study to confirm the correlation of clinical benefit rate(CBR) and cancer related factors in the use of Fulvestrant as a second line treatment for postmenopausal advanced and recurrence breast cancer
Latest Information Update: 25 Oct 2019
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacodynamics
- 23 Oct 2019 Status changed from recruiting to discontinued.
- 30 Oct 2013 New trial record